ZEVRA THERAPEUTICS, INC.
ZVRANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ZVRA. That does not mean none is planned.
Get an email about ZVRA's next catalysts
Track ZEVRA THERAPEUTICS (ZVRA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ZVRA Earnings Report
EPS Est: $0.14 | FQ end Sep/2026 | Call: amc
Market Overview
Stock performance and key metrics
KP415 oral capsule
ADHD
Serdexmethylphenidate
Idiopathic Hypersomnia
Sodium phenylbutyrate
Medium-chain Acyl-CoA Dehydrogenase Deficiency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KP415 oral capsule | Phase 3 | ADHD | - | - |
Serdexmethylphenidate | Phase 2 | Idiopathic Hypersomnia | - | Patent 2038 |
Sodium phenylbutyrate | Phase 2 | Medium-chain Acyl-CoA Dehydrogenase Deficiency | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ZEVRA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ZEVRA THERAPEUTICS, INC.'s (ZVRA) pipeline across Phase 3, Phase 2. Its lead program is KP415 oral capsule (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ZEVRA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ZEVRA THERAPEUTICS, INC. (ZVRA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ZVRA biotech catalysts?→
Add ZVRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ZEVRA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.